argenx SE (EBR:ARGX)
795.20
+6.60 (0.84%)
Nov 19, 2025, 3:24 PM CET
argenx SE Revenue
argenx SE had revenue of $1.15B USD in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.68B, up 92.98% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$3.68B
Revenue Growth
+92.98%
P/S Ratio
15.37
Revenue / Employee
$2.30M
Employees
1,599
Market Cap
48.26B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
| Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| Fagron NV | 918.75M |
| Ion Beam Applications | 585.76M |
| European Medical Solutions | 49.47M |
| Biocartis Group NV | 47.69M |
| Hyloris Pharmaceuticals | 8.46M |
| Nyxoah | 5.64M |
| Onward Medical | 2.72M |
argenx SE News
- 16 hours ago - $1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today - Benzinga
- 1 day ago - Citigroup Boosts Price Target for ARGX While Maintaining Buy Rating | ARGX Stock News - GuruFocus
- 2 days ago - PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 4 days ago - Wedbush Raises Price Target for ARGX to $1000, Maintains Outperform Rating | ARGX Stock News - GuruFocus
- 8 days ago - KROS vs. ARGX: Which Stock Is the Better Value Option? - Nasdaq
- 11 days ago - ARGX: JP Morgan Raises Price Target, Maintains Overweight Rating | ARGX Stock News - GuruFocus
- 13 days ago - Baron International Growth Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 13 days ago - Argenx Gains Health Canada Approval For Vyvgart SC As Monotherapy In CIDP - Nasdaq